Engineered Oncolytic Viruses Expressing Immunomodulatory Genes Enhances In Vitro Anti-Tumor Cellular Immune Responses
While chemo- and radio-therapy are considered the first-line of treatment for most cancers, its serious side effects have led to continuous innovation and discovery of new anti-tumor treatments. Oncolytic viruses (OVs) possess a magnitude of mechanism of action to elicit anti-tumor immune response, including OVs innate cytotoxicity and enhanced anti-tumor immunity by inserting immunomodulatory genes. Moreover, there are no deaths or serious adverse events in clinical so far.
Here we evaluated the effect of modified OVs (mOVs) with various immunomodulatory genes on oncolytic capability and cellular immune responses in vitro. Our results indicate mOVs infected cancer cells more readily activates various immune cells, including T, natural killer (NK) and monocyte-derived dendritic cells (moDC), promoting a stronger response in immune cell proliferation and secretion of inflammatory cytokines such as IFN-γ.
Engineered oncolytic viruses expressing immunomodulatory genes enhances in vitro anti-tumor cellular immune responses